From a pharmacological point of view, it is also noteworthy that one of the proposed mechanisms of SGLT2 inhibition treatment to ameliorate the risk of HF may be related to its ability to increase ketone body availability to the myocardium.29 This evidence concerns the gene SLC5A2 and hydrops fetalis.